Anika’s Post

Learn how Hartford HealthCare’s orthopedic navigators are leveraging Force Therapeutics to drastically reduce manual work and more effectively prepare for the CMS mandate: https://lnkd.in/eedG89XX

Dr. Roman Trimba of OrthoCincy Orthopaedics & Sports Medicine performed a two-level case to address his patient's adjacent segment disease with severe low back pain and lumbar radiculopathy. The surgical plan consisted of an L3-L4 XLIF™ and L5-S1 ALIF leveraging our Maxcess™ 4 and Supine ALIF access systems. Dr. Trimba utilized our porous titanium (Ti) implants, Modulus™ XLIF™ and Modulus™ ALIF, which are designed to provide a favorable environment for bone ingrowth* while enhancing visualization compared to traditional Ti implants. The patient has reported no pain one year postoperatively and is back to enjoying physical activities! * Preclinical data on file. Data may not be representative of clinical results. TR 9604787. #ModulusALIF #ModulusXLIF #MaXcess4 #LumbarRadiculopathy #GlobusMedical #LifeMovesUs

Welcome to the ATiO Early-Stage Pitch Contest! An annual event designed to showcase and support the most emerging companies in orthopaedics. This competition distinguishes itself by not only highlighting innovative products and technologies - but also by creating a dynamic interaction among a diverse group of professionals from various sectors within the orthopaedic community. This unique competition invites a select group of innovative companies to pitch their products and innovations to a diverse audience, which then participates in a community vote to determine the most promising prospects. Participants have the opportunity to present their companies and innovations in a concise 7-minute presentation, followed by a 3-minute question-and-answer session. This allows them to further explain their contributions and engage directly with the audience's questions and feedback. The competition culminates in a group voting process during the finals, where the winning company is recognized for its contributions to orthopaedic innovation. This event serves as a catalyst for collaboration, growth, and the advancement of orthopaedic therapies. #ATiOAward2024 #OrthopaedicTherapies #ATiOEarlyStagePitchContest

The Orthopaedic Devices industry remains an attractive field for private equity investors for two prime reasons... 1️⃣ Market growth from aging population and untapped opportunities in emerging markets 2️⃣ Regulatory and R&D entry barriers favouring incumbent players We uncover market trends like these in our upcoming webinar, “A Deep Dive into Orthopaedic Devices,” on February 19th at 15:00 CET. Register today to hold your spot! ✍️ Register here: https://okt.to/i7vRq1 🕒 Time: February 19th, 15:00 - 15:30 CET #marketreport #orthopaedicdevices #investorinsights

In this panel, Orthopedic Quality Experts share how their organizations effectively manage navigators’ workloads while accommodating new regulatory responsibilities. Watch here: https://lnkd.in/e6dMaWXT #CMS #PROMs #MSK

🌐 In 2012, a novel PROM called Patients' Joint Perception (PJP) was introduced for arthroplasty patients. PJP is a simple, single-item measure to assess patients' views of their joints compared to a natural joint. Our recent study validates PJP as a reliable tool for evaluating patient outcomes after ACL reconstruction. Its simplicity and effectiveness make it a valuable measure for assessing ACLR outcomes. We thank the prestigious KSSTA Journal, one of the top ten orthopedic journals, for publishing our work. Link: https://lnkd.in/eEwyiZZZ

Transforming Orthopaedic Therapy Across Borders We are excited to share a case study that showcases our commitment to driving global healthcare forward. Spearheading a strategic journey, we've paved the way for an EU-based med-tech startup's Orthopaedic Therapy Device from its initial stages to international markets.   🌍 Challenge: Navigating the intricate web of international reimbursement strategies for a device set to revolutionise orthopaedic trauma therapy and rehabilitation.   🔍 Solution: Leveraging inXso's expertise, we embarked on a meticulous analysis and strategic formulation that spanned across continents. From comprehensive market assessments in Europe to exploring avenues in key global markets, our mission was to identify the optimal path for product launch and revenue generation.   💡 Impact: Our efforts culminated in a robust international reimbursement strategy, pinpointing six countries for successful market entry. This strategic endeavour not only promises a brighter future for orthopaedic care but also ensures a swift journey to market success and revenue realisation for our clients.   Dive deeper into our strategic approach and the transformative impact of this project! #medicalinnovation #reimbursement #OrthopaedicInnovation #HealthcareStrategy #MedTech #inXso  #InternationalMarketAccess #inXsoSuccess

On behalf of Hoag Orthopedic Institute, we are pleased to share our 2023 Annual HOI Outcomes Report. We are proud to share our program development and outcomes from 2022-2023. HOI continues to focus on quality outcomes, patient experience, performance improvement, education and research. These are all foundational components of our organization, which is heading into its 13th year of operation. View the 2023 Outcomes Report here: hoioutcomes.com/2023. #HoagOrthopedicInstitute #HOI #PatientOutcomes #OutcomesReport

Understanding the key factors that influence PRP outcomes is key to maximizing its benefits. This article outlines 15 essential data points to better evaluate PRP kits and protocols. A must-read for anyone looking to optimize regenerative treatments! 💡 #PRP #RegenerativeMedicine #ClinicalInsights #HealthTech"

📄 Research Report   Petra Capital Pty Ltd has released an independent analyst report, forecasting Orthocell’s potential to reach A$1.28 per share. Highlighting the attractive commercial opportunity for SmrtGraft™, Orthocell’s tendon repair product, the author notes: “OCC’s SmrtGraft™ tendon product application for approval in Australia opens up a potential third product revenue stream for the CelGro™ platform and is currently not in our forecasts. For use by Orthopaedic surgeons, we see distribution as well as manufacturing synergies with OCC’s Remplir nerve product. As such, it represents a potential attractive revenue stream without much additional cost. With OCC on track for US approval of Remplir in 1QCY25, our TP of $1.28/sh offers >3x upside.”   Take a closer look 👉 https://lnkd.in/gCwyNn8F   $OCC #innovation #biotech #pharma #regenerativemedicine #healthcare